NTC
GBT

NF Trinity Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

NF Trinity Capital’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-250,000
Closed -$7.76M – 61
2017
Q3 		$7.76M Buy
+250,000
New +$7.03M 1.11% 25

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NF Trinity Capital's GBT Position: Q4 2017 in Review

NF Trinity Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2017, closing a stake of 250,000 shares — an estimated $7.76M sold.

NF Trinity Capital first reported a position in GBT in Q3 2017 and held it in 1 quarter. The position peaked at $7.76M in Q3 2017. 157 funds tracked by Wall St. Rank hold GBT as of Q4 2017.

  • NF Trinity Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • NF Trinity Capital sold 250,000 Global Blood Therapeutics, Inc. shares in Q4 2017, an estimated $7.76M.
  • NF Trinity Capital first reported a position in Global Blood Therapeutics, Inc. in Q3 2017 and held it in 1 quarter.
  • NF Trinity Capital's Global Blood Therapeutics, Inc. position peaked at $7.76M in Q3 2017.
  • 157 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2017.

Based on NF Trinity Capital's 13F filing for Q4 2017, filed 6 Feb 2018.